Abstract 543P
Background
Interstitial pneumonia (IP) is the common and poor prognostic comorbidities in patients with non-small cell lung cancer (NSCLC) and is a known risk factor for immune checkpoint inhibitor (ICI)-induced pneumonitis. The aim of this study is to assess the incidence, severity and risk factors for pneumonitis induced by immune checkpoint inhibitor (ICI) monotherapy in NSCLC patients with idiopathic IP.
Methods
This is a multicenter, retrospective study in patients with (1) advanced or recurrent NSCLC, (2) comorbid idiopathic IP, and (3) receiving ICI monotherapy as second-line or later therapy. All CTs at baseline and at the onset of pneumonitis were centrally adjudicated by a board-certified radiologist. We performed logistic regression analysis to identify risk factors for pneumonitis using clinical characteristics, laboratory data and radiological findings as variables.
Results
Sixty-five patients were analyzed, with a median age of 71 years, and 98.5% had a smoking history. Sixty percent received nivolumab, 21.5% received atezolizumab and 18.5% received pembrolizumab. The median cycle of ICI was 4 cycles. Radiological patterns of IP were UIP (11%), probable UIP (15%), indeterminate for UIP (51%), alternative (23%), respectively, with 23% having honeycomb lung and a median %FVC of 95%. The incidence of pneumonitis was 23.1% for all grade and 13.9% for ≥grade3. We could not identify any significant risk factors for ICI-induced pneumonitis in the multivariate logistic regression analysis. There was no difference in the incidence and severity of ICI-induced pneumonitis when comparing patients with and without honeycomb lung, or with FVC ≥80% and <80%.
Conclusions
There was no difference in the risk of ICI-induced pneumonitis according to specific findings, including the radiological pattern of comorbid IP, the presence of honeycomb lung, and pulmonary function tests. ICIs should be carefully administrated in NSCLC with any types of comorbid IP.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Ikeda: Financial Interests, Personal, Advisory Board: AstraZeneca, Chugai, Ono, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai, Ono, Bristol Myers Squibb, Taiho, Eli Lilly, Pfizer, Boehringer Ingelheim, Takeda; Financial Interests, Personal, Research Grant: AstraZeneca, Chugai. J. Sakakibara-Konishi: Financial Interests, Personal, Research Grant: eli Lilly. K. Yokoo: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai, Eli Lilly, Kyowa Kirin, MerckBiopharma, Novartis, Terumo, Takeda, Nippon Kayaku, Bristol Myers Squibb. T. Iwasawa: Financial Interests, Personal, Advisory Board: CANON Medical Systems, Ziosoft I; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim. T. Misumi: Financial Interests, Personal, Invited Speaker: Miyarisan. T. Ogura: Financial Interests, Personal, Invited Speaker: Japanese Boehringer Ingelheim, Shionogi; Financial Interests, Personal, Advisory Board: BMS, Japanese Boehringer Ingelheim, Taiho, Shionogi. All other authors have declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract